Shots:

• Ainos reported the commencement of clinical evaluation for novel Veldona-based drugs to treat feline chronic gingivostomatitis (FCGS). The trials will run for ~10mos., from May 24, 2024 to Mar 31, 2025
• The study aims at improving health evaluations by both pet owners & veterinarians post-treatment among cats (n=30), divided into low (6000 IU/time) & high dose (12000 IU/time) treatment arms, & assessing the ability of steroids or other immunosuppressive drugs' reduced dosage & frequency   
• The prior studies have confirmed partial immune system regulation with interferon’s oral mucosal administration in experimental animals, depicted its proper distribution in head & neck lymph nodes as well as mesenteric lymphatic systems plus minimizing immunogenicity & bone marrow suppression

Ref: Ainos | Image: Ainos

Related News:- Siemens Healthineers Receives the US FDA Approval for Biograph Vision.X PET/CT Scanner

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com